Chaim Hurvitz - 30 Aug 2023 Form 4 Insider Report for NRX Pharmaceuticals, Inc. (NRXP)

Reporting relationship: Director
Issuer ticker: NRXP
Reported as of: 30 Aug 2023
Net transaction value: +$20,125
SEC form: 4
Accepted by SEC: 11 Sep 2023, 09:15:13 UTC
Prior SEC filing: 27 Sep 2023
Next SEC filing: 25 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Chaim Hurvitz

Key filing fact

Chaim Hurvitz filed Form 4 for NRX Pharmaceuticals, Inc. (NRXP) on 11 Sep 2023.

Key facts

This page summarizes Chaim Hurvitz's Form 4 filing for NRX Pharmaceuticals, Inc. (NRXP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 11 Sep 2023, 09:15.

Change

Previous filing in this sequence was filed on 27 Sep 2023.
Current net transaction value: +$20,125.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NRXP transaction

Common Stock, par value $0.001 per share

Purchase

Transaction value: $20,125
Shares: +70,000
Change %: +14%
Price: $0.2875
Shares after: 570,000
Date: 30 Aug 2023
Ownership: Direct
Footnotes: F1

NRXP holding

Common Stock, par value $0.001 per share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,436,350
Date: 30 Aug 2023
Ownership: By Shirat HaChaim Ltd.
Footnotes: F2

NRXP holding

Common Stock, par value $0.001 per share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 208,443
Date: 30 Aug 2023
Ownership: By CH Health-Private Venture Capital Ltd.
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.

Footnote F2

Chaim Hurwitz is the owner of Shirat HaChaim Ltd.

Footnote F3

Chaim Hurwitz is the owner of CH Health-Private Venture Capital Ltd.